Ontuxizumab Biosimilar Monoclonal Antibody (CD248) for Research
Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-405-1mg | 1mg | 618 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody |
| INN Name | Ontuxizumab |
| Target | CD248 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA) |
| Conditions Approved | na |
| Conditions Active | Colorectal cancer;Malignant melanoma;Soft tissue sarcoma |
| Conditions Discontinued | Lymphoma;Solid tumours |
| Development Tech | na |
About target - CD248
1. Protein Endosialin
2. Gene CD248
3. Organism Homo sapiens (Human)
Function
May play a role in tumor angiogenesis.

